Evaluation of Novel N-(Dibenzylcarbamothioyl)benzamide Derivatives as Antibacterial Agents by Using DFT and Drug-Likeness Assessment

Table 1

Antibacterial screening of compounds 2a, 2b, 2c, and 2d.

Compound	Gram-positive bacteria (mm)/concentration of sample (mg/mL)
	Staphylococcus aureus	Enterococcus faecalis	Bacillus subtilis
2a	—	—	—
2b	11 ± 0.8 (50 mg/ml)	—	8 ± 0.4 (50 mg/ml)
2c	—	—	—
2d	—	—	—
Positive control (chloramphenicol)	30.1 ± 0.0 (50 mg/ml)	20.0 ± 0.0 (50 mg/ml)	32.8 ± 0.0 (50 mg/ml)

“—” denotes no activity.